Ionis Pharmaceuticals, Inc.

NASDAQ:IONS

Biotechnology

Healthcare
$27.39 +1.67%

+$1.22 today

Market cap
$4.56B
Beta
0.37
P/E (TTM)
-37.5
EPS (TTM)
-$1.98
52W Low $36.45High $86.74

Volume 3.23M

Average 1.83M

IONS EBITDA Margin

EBITDA as a percentage of revenue.

Ionis Pharmaceuticals, Inc.NASDAQ: IONS

EBITDA Margin · Q3 FY2026 · quarter ended Sep 2026

EBITDA Margin widens to -40.0%

EBITDA Margin was -40.0% in Q3 FY2026, up 26.0 pp from a year earlier. On a trailing-twelve-month basis it was -49.3%, down 33.5 pp year over year. Over 3 fiscal years it widened by 8.7 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 18 analysts of -48.0% for the fiscal year ending Dec 2026, down from -30.1% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-40.0%-0.7 pp QoQ
Last fiscal yearDec 2025
-30.1%+20.0 pp YoY
LTMSep 2026
-49.3%-33.5 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+26.0 pp+69.9 pp+43.9 pp
1 year+20.0 pp-17.9 pp-37.9 pp
3 years+8.7 pp+46.5 pp+37.8 pp
5 years+63.1 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-30.1%
Year-over-year change
+20.0pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How IONS compares with its peers on the latest reported figures

  • IONS's LTM Sep 2026 EBITDA Margin of -49.3% is the 6th highest of the 9 companies compared; the peer median is -1.1%.
  • Its year-over-year change of -33.5 pp is the lowest of 9, against a peer median of +5.7 pp.
  • Over three fiscal years its change of +8.7 pp compares with a peer median of +104.9 pp.
IONS Competitors Peer median
EBITDA Margin for IONS and competitors
Company Period LTM level YoY 3-year change
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 202624.0% +30.9 pp+106.3 pp
BIIBBiogen Inc.LTM Jun 202619.7% -14.2 pp-4.7 pp
PTCTPTC Therapeutics, Inc.LTM Jun 202617.2% -30.5 pp+103.9 pp
SRPTSarepta Therapeutics, Inc.LTM Mar 20265.7% +10.5 pp+34.3 pp
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026-8.0% -32.9 pp+5.1 pp
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-49.3% -33.5 pp+8.7 pp
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026-75.2% +1.0 pp+105.9 pp
BBIOBridgeBio Pharma, Inc.LTM Jun 2026-85.7% +187.2 pp+377.1 pp
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-581.9% +549.6 pp+308.9 pp
Peer median (excluding IONS) -1.1%+5.7 pp+104.9 pp

Competitors are the stored peer set for IONS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue810.46M587.37M787.65M705.14M944M
Cost of Revenue10.84M14.12M9.13M11.22M16M
Gross Profit799.61M573.25M778.51M693.92M928M
Gross Margin98.7%97.6%98.8%98.4%98.3%
Research & Development643M833M899.63M901.53M916M
Selling, General & Admin170.9M150.3M232.6M267.5M394M
Operating Expenses829.8M983.44M1.13B1.17B1.31B
Depreciation & Amortization19.56M22.11M22.5M21.99M22.69M
EBITDA(5.19M)(227.76M)(235.87M)(353.72M)(284.31M)
EBITDA Margin-0.6%-38.8%-29.9%-50.2%-30.1%
Operating Income(30.19M)(410.19M)(353.73M)(475.08M)(382M)
Operating Margin-3.7%-69.8%-44.9%-67.4%-40.5%
Interest Income10.04M25.33M89.04M107.02M97.77M
Interest Expense9.35M8.12M81.46M90.45M90.54M
Other Income / Expenses1.04M152.21M19.77M15.01M2M
Income Before Tax(29.15M)(257.99M)(333.97M)(460.07M)(380M)
Pre-Tax Margin-3.6%-43.9%-42.4%-65.2%-40.3%
Income Tax Expense(551K)11.74M32.32M(6.17M)1M
Net Income(28.6M)(269.72M)(366.29M)(453.9M)(381M)
Net Margin-3.5%-45.9%-46.5%-64.4%-40.4%
EPS (Basic)(0.20)(1.90)(2.56)(3.04)(2.38)
EPS (Diluted)(0.20)(1.90)(2.56)(3.04)(2.38)
Weighted Avg Shares141.02M141.85M143M149.51M160M
Weighted Avg Shares (Diluted)141.02M141.85M143.19M149.51M160M

Ionis Pharmaceuticals, Inc.

NASDAQ:IONS

Intrinsic Alpha fair value

Locked

Current Price

$27.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.